Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib versus platinum-based chemotherapy in first-line EGFR exon 20 insertion NSCLC
NL-OMON59677Phase 3Active, not recruiting
- Sponsor
- ArriVent BioPharma
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of furmonertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by ArriVent BioPharma. Primary endpoint: Progression-free survival. Started Jun 2023; status: active, not recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59677.